Targeting HER 1 and 2 in breast cancer with lapatinib
Numerous clinical trials support the biological relevance of the HER2 oncoprotein in breast cancer. In spite of improved outcomes, overexpression of the receptor is associated with increased risks of disease relapse, even in patients with early, and potentially curable, disease. Until recently, deve...
Na minha lista:
| Hovedforfatter: | |
|---|---|
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Frontiers Media S.A.
2011-12-01
|
| Serier: | Oncology Reviews |
| Fag: | |
| Online adgang: | http://www.oncologyreviews.org/index.php/or/article/view/105 |
| Tags: |
Ingen Tags, Vær først til at tagge denne postø!
|